Vaccine Info

Trumenba Meningitis B Vaccine

Authored by
Fact checked by
Robert Carlson, MD


Trumenba is a sterile suspension composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and one from subfamily B (A05 and B01, respectively).


Trumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B.


Trumenba is intended for intramuscular injection administered as a three-dose series in individuals 10-25 years of age following a 0-, 2-, and 6-month schedule.

On October 29, 2014, the U.S. Food and Drug Administration sent an approval letter authorizing the introduction or delivery of Trumenba into interstate commerce.



Clinical Trials

No clinical trials found